For pharmaceutical companies

Target compounds that truly matter.

Use the correct de-risking strategy and bring new biotherapeutics to the market faster by introducing ultraprecise immunogenic profiling (MAPPS) into the early stages of your drug development process.

Learn More

Early identification of immunogenic peptides for enhanced compound selection and R&D strategy

Accelerate the drug development process by identifying immunogenic peptides, such as neo-antigens and viral antigens, at an early stage. This enables the selection of compounds that can trigger desired immune responses. Having an understanding of a biotherapeutic's immunogenic profile facilitates the establishment of a robust R&D strategy, ensuring a seamless transition to the next stages of the drug development process.

Unlocking immunogenic epitopes: optimizing biotherapeutic effectiveness and safety

Gain a thorough understanding of a biotherapeutic's immunogenic epitopes to enhance its effectiveness and safety.

ImmuneSpec's innovative approach combines comprehensive immunogenic analysis with expert knowledge to provide a unique solution for optimizing biotherapeutics. Our advanced MAPPS report includes detailed information about specific immunogenic areas, allowing biotherapeutic optimization with minimal modifications.

Demonstrate safety, quality and efficacy of drug candidate to regulatory authorities and investors.

Utilize ImmuneSpec's advanced platform to gain a better understanding of the immunogenicity of your biotherapeutic. This facilitates the evaluation of its safety and efficacy, leading to faster identification of potential adverse effects.

Our data supports the demonstration of safety and efficacy of biotherapeutic candidates to regulatory authorities and investors, ensuring market access and securing funding for further developments.

Applications

Explore immunopeptides within your specialized research domain.

Discover immunogenic characteristics of a compound, whether it is aimed at evading or enhancing an immune response.

"I was blown away by the level of expertise, the great communication, thought partnership and superior results. ImmuneSpec was able to handle highly complex experimental designs, large numbers of samples and provide the highest peptide yields, while being faster than any other company we have worked with in the past."

Daniel Leventhal

Generate Biomedicines

Because antigen discovery for the large and complex parasite ‘Leishmania’ has known a deadlock for many decades, we approached the ImmuneSpec team to undertake immunopeptidomics analysis on skin biopsies and organ aspiration samples from leishmania patients. They tackled the challenging starting material with great enthusiasm and successfully created the first-ever mapping of biologically presented peptides in leishmaniasis patients. This will significantly expedite vaccine development for this neglected tropical disease affecting remote and impoverished communities.

Wim Adriaensen

Institute of Tropical Medicine Antwerp

“We are excited to partner with an outstanding team of scientists who provide cutting-edge immunopeptidomics services with remarkable flexibility and timely delivery”

Sofie Pattijn

ImmunXperts

"Encouraged by recent publications that many lncRNA-derived peptides could be more precisely detected with HLA-I peptidomics, our team reached out to the ImmuneSpec team. We selected the team among a range of companies as they provide full service - from MHC complex purification to refining MS results for identification of peptides with highest quality. They have access to one of the most precise MS instruments for such specific scientific questions and are very dedicated to give exhaustive information and are very proactive on all the steps of analysis."